What is it about?
Elagolix is a GNRH antagonist taken orally to treat pain symptoms associated with endometriosis. This reports the baseline burden of pain for women enrolled in the phase III trials of this medication.
Featured Image
Why is it important?
The burden of this disease, endometriosis is significant. Impact on a women's quality of life is as significant as many other human diseases.
Perspectives
Broader recognition of the significant impact of endometriosis is critical to health policy makers and to funding sources for additional research on this enigmatic, highly prevalent disorder.
Professor Nicholas Albert Leyland
McMaster University
Read the Original
This page is a summary of: Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials, Journal of Endometriosis and Pelvic Pain Disorders, July 2019, SAGE Publications,
DOI: 10.1177/2284026519864232.
You can read the full text:
Contributors
The following have contributed to this page
